6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of March 2016 (Report no. 1)

Commission File Number: 000-30820

TIKCRO TECHNOLOGIES LTD.

(Translation of registrant’s name into English)

7 Sapir Street, 5th floor, Nes Ziona 7403630 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x             Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): N/A

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): N/A

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes    o        No  x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A

CONTENTS

This report on Form 6-K of the Registrant consists of the following document, which is attached hereto and incorporated by reference herein:

Exhibit

Number Description of Exhibit

99.1 Press release: Tikcro Technologies Reports Fourth Quarter and Year End 2015 Results, dated March 31, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIKCRO TECHNOLOGIES LTD.
Date: March 31, 2016	By:	/s/ Aviv Boim
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Press release: Tikcro Technologies Reports Fourth Quarter and Year End 2015 Results, dated March 31, 2016.

EX-99.1

Exhibit 99.1

	PRESS RELEASE
For more information contact:
Investor Relations Garth Russell KCSA Strategic Communications (212) 896-1250 grussell@kcsa.com

Tikcro Technologies Reports Fourth Quarter and Year End 2015 Results

Tel Aviv, Israel, March 31, 2016 - Tikcro Technologies Ltd. (OTCQX: TIKRF) today reported financial results for the fourth quarter and the year ended December 31, 2015.

Aviv Boim, CEO of Tikcro, commented, “In the quarter, we continued to make progress with pre-clinical development of functional antibodies for cancer immune modulators. Leveraging a unique approach for the generation of antibodies, we aim to bring functional antibodies with exclusive blocking qualities to a number of targeted domains. In the quarter, we commenced research activities from our new facilities at the Kiryat Weizmann Science Park in Israel."

Net loss for the fourth quarter of 2015 was $205,000, or $0.02 per diluted share. Net lossfor the full year ended December 31, 2015 was $885,000, or $0.10 per diluted share.

As of December 31, 2015, the company reported $8.6 million in cash and cash equivalents.  This cash balance includes gross proceeds from the capital raise in the fourth quarter of 2015 of $600,000 for 980,000 ordinary shares. As of December 31, 2015 the company reported 9,878,861 shares of common stock outstanding.

About Tikcro Technologies:

Tikcro Technologies Ltd. (OTCQX: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies blocking of cancer immune modulator pathways. For more information about Tikcro, visit Tikcro’s website at www.tikcro.com.

Safe Harbor Statement

Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the risks related to early stage biotechnology projects, including, but not limited to, obtaining required licenses at reasonable commercial terms, the development, testing, regulatory approval and commercialization of our proposed products, intellectual property rights, competition, exposure to lawsuits and dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Form 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods.  We undertake no duty to update any forward-looking information.

Tikcro Technologies Ltd.

 Condensed Balance Sheets

(US dollars in thousands)

	December 31, 2015		December 31,  2014
	Unaudited		Audited
Assets
Current assets
Cash and cash equivalents	$	8,560	$	8,722
Other receivables		123		25
Investment in BioCancell		50		85
Total current assets		8,733		8,832
Property and equipment, net		67		88
Total assets	$	8,800	$	8,920
Liabilities and Shareholders' Equity
Current liabilities
Other current liabilities	$	226	$	184
Shareholders' equity		8,574		8,736
Total liabilities and shareholders' equity	$	8,800	$	8,920

Tikcro Technologies Ltd.

Statements of Operations

(US dollars in thousands, except per share data)

	Three Months Ended  December 31,						Year Ended  December 31
	2015			2014			2015			2014
Research and development expenses	$	25		$	17		$	247		$	89
General and administrative expenses, net		179			101			609			348
Total operating expenses		204			118			856			437
Operating loss		(204	)		(118	)		(856	)		(437	)
Financial expenses, net		(1	)		(171	)		(29	)		(240	)
Net loss	$	(205	)	$	(289	)	$	(885	)	$	(677	)
Basic and diluted net loss per share	$	(0.02	)	$	(0.03	)	$	(0.10	)	$	(0.08	)
Weighted average number of shares used computing basic and diluted loss per share		8,848			8,837			8,840			8,832